EN DE

Top Eminent Healthcare Group (6877) Fair Value & Analysis

Financial Services · HK · Market cap HK$209M

TE Top Eminent Healthcare Group 6877 · HK
PriceHK$0.1040
Fair ValueHK$0.1074
Upside+3.3%
Quality55/100
Watch Top Eminent Healthcare Group for free, get notified when fair value or trend changes. Watch for free
Expensive Growth
Loss-making · -6.5% net margin
Low debt · negative free cash flow
Ranks above peers (6/10)
Narrow moat 1/100
Evidence: Low Range HK$0.0722 – HK$0.1338 Share as image

Fair value as of: Aug 6, 2026

From 1 valuation models · updated 4 days ago

Fair value updated Aug 6, 2026, revised from HK$0.1100 to HK$0.1074 (−2.4%) since Jul 2, 2026. Share price +4.0% over the past month.

A solid business, currently priced close to our fair value.

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • A fairly wide model range (HK$0.0722 to HK$0.1338) leaves room in how you read the outcome.
  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
  • For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$0.5100 HK$0.0510 Fair Value HK$0.1074 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 6, 2026.

How to read this chart

60‑month range HK$0.0510 – HK$0.5100 · fair‑value band HK$0.0722 – HK$0.1338 · the HK$0.1040 price screens below the HK$0.1074 fair value. Dashed = 300-day average. As of Aug 6, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Top Eminent Healthcare Group (6877) currently trades at HK$0.1040, while our model-based Fair Value estimate is HK$0.1074, implying the stock looks roughly 3.3% fairly valued today. The Quality Score stands at 55/100 (solid quality), in the Financial Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

Over the trailing twelve months, Top Eminent Healthcare Group generated revenue of HK$110M at a net margin of -6.5%. Revenue grew 60.5% year over year. It earns a return on equity of -2.9%. The balance sheet holds a net cash position of HK$208M. Fundamentals as of Aug 6, 2026

Our scenario range runs from HK$0.0722 (bear case) to HK$0.1338 (bull case); at HK$0.1040, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 71% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Financial Services peers we cover trades at 11% fair-value upside, at 3%, 6877 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
NCAV (Graham) HK$0.0600 HK$0.0800 HK$0.1200 50
All 1 models by family
Asset-Based
NCAV (Graham) HK$0.0600 HK$0.0800 HK$0.1200 50

Notify me when 6877 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$110M
Revenue growth (YoY) +60.5%
Net margin -6.5%
Return on equity -2.9%
Free cash flow −HK$683K FY2025
Operating margin -9.2%
More key figures
EPS growth (YoY) +18.4%
Net cash HK$208M FY2025

Figures from reported company fundamentals · as of Aug 6, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 55/100

Of which business quality 56 · Market factors (momentum, volatility) 5

Profitability 14
Margins and returns on capital today
Quality Growth 63
Are margins and returns improving?
Cashflow 9
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 98
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 10
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Top Eminent Healthcare Group Limited, an investment holding company, sells healthcare products and other services in Australia, Hong Kong, and New Zealand. It operates through the healthcare business and unallocated segment segments. The company also provides molecular tea, Ganoderma lucidum, brain protection capsules, and natural factors.

Full company description

Top Eminent Healthcare Group Limited, an investment holding company, sells healthcare products and other services in Australia, Hong Kong, and New Zealand. It operates through the healthcare business and unallocated segment segments. The company also provides molecular tea, Ganoderma lucidum, brain protection capsules, and natural factors. Top Eminent Healthcare Group Limited was formerly known as CLSA Premium Limited and changed its name to Top Eminent Healthcare Group Limited in May 2025. Top Eminent Healthcare Group Limited was incorporated in 2010 and is headquartered in Wan Chai, Hong Kong. As of April 1, 2025, Top Eminent Healthcare Group Limited operates as a subsidiary of Beijing Tong Ren Tang (Cayman) Limited.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Top Eminent Healthcare Group reported revenue of HK$110M in FY2025 versus HK$5.4M in FY2021, a compound +112.0%/yr. Reported net income was −HK$7.1M in FY2025.

Growth Quality 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2025)
HK$110M
Latest YoY
+27.0%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+41.1%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+87.7%
Avg. growth/yr (13Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+1.0%
Revenue +112.0%/yr
FY21 HK$5.4M
FY22 HK$39.1M
FY23 HK$191M
FY24 HK$86.5M
FY25 HK$110M
Net income
FY21 −HK$56.5M
FY22 −HK$31.1M
FY23 HK$9.8M
FY24 HK$11.3M
FY25 −HK$7.1M

Watch 6877: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Top Eminent Healthcare Group Fair Value". https://www.fairvalue-calculator.com/stock/6877

Peer Group

Capital Markets · 423 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 56 · Above median
Fair Value upside +6% · Above median
Return on assets -3% · Bottom 25%
Net margin (TTM) -6% · Bottom 25%
Operating margin (TTM) -9% · Bottom 25%
Revenue growth 61% · Above median

Valuation Multiples vs Capital Markets median · lower = cheaper

P/B 0.11× · Cheaper than 75% of peers
P/S (TTM) 0.24× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 41 · sector 9
FUTURE 100 · sector 96
PAST 0 · sector 30
HEALTH 100 · sector 93
DIVIDEND 0 · sector 36

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Capital Markets stocks, each showing price versus our Fair Value estimate (as of Aug 6, 2026).

Stock Price Fair Value vs Fair Value
Huatai Securities Co HTSC $0.2700 $0.0400 -85%
Mirae Asset Securities Co 006800 38,750 KRW 31,645 KRW -18%
Meritz Financial Group 138040 117,000 KRW 87,706 KRW -25%
Korea Investment Holdings 071050 239,000 KRW 318,825 KRW +33%
NH Investment & Securities Co 005940 31,000 KRW 37,133 KRW +20%
Samsung Securities Co 016360 107,700 KRW 126,487 KRW +17%
Motilal Oswal Financial Services Limited MOTILALOFS ₹967.00 ₹299.65 -69%
Kiwoom Securities Co 039490 322,000 KRW 358,091 KRW +11%
SSI Securities Corporation SSI 24,250 VND 28,021 VND +16%
Bolsas y Mercados Argentinos S.A BYMA 313.75 ARS 120.22 ARS -62%

Compare Top Eminent Healthcare Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Financial Services stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Top Eminent Healthcare Group (6877) overvalued or undervalued?
As of Aug 6, 2026, our model estimates a fair value of HK$0.1074 versus a price of HK$0.1040, about +3% (fairly valued).
What is the fair value of 6877?
Our model-based fair value for Top Eminent Healthcare Group is HK$0.1074 (as of Aug 6, 2026), built from audited fundamentals. The current price is HK$0.1040.
What is the quality score of 6877?
Top Eminent Healthcare Group has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Top Eminent Healthcare Group (6877)?
Top Eminent Healthcare Group reported trailing-twelve-month revenue of about HK$110M (latest available figure, as of Aug 6, 2026).
What is the net profit margin of 6877?
The net profit margin of Top Eminent Healthcare Group is about -6.5%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Top Eminent Healthcare Group and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.